Candel Therapeutics - התחייבויות לטווח ארוך של החברה CADL

Candel Therapeutics (CADL) is developing methods to combat brain and prostate tumors, relying on payments from government funds and insurers. The company is currently spending its raised capital, as it has no commercial products. This daily price chart on GURU.Markets captured the 0.05 metric. Looking ahead, the business plans to expand its oncology presence by scaling viral therapy and successfully completing medical trials.

This indicator reflects the total volume of long-term liabilities, determining the actual financial burden on the business over a multi-year horizon. Analyzing the company's long-term debt allows for an assessment of capital structure stability and liquidity risks during market volatility. The metric measures the issuer's ability to service loans without compromising operational activities. For Candel Therapeutics (CADL), this is critical when maintaining costly cold chains and adhering to strict clinic supply protocols.